NSG BioLabs announces partnership with Eppendorf Group

Eppendorf and NSG BioLabs have entered a strategic partnership to foster an environment where NSG BioLabs' residents can thrive.

NSG BioLabs, Singapore’s largest provider of biotech co-working laboratory and office space, announces a new partnership with Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, to support biotech startups by providing needed resources such as product and applications expertise and its networks […]

Progentos Therapeutics closes USD 65MLn in series A financing

Progentos Therapeutics Closes $65 Million Series A Financing to Advance Treatments for Multiple Sclerosis and Other Degenerative Diseases

Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, recently announced its launch and the closing of a $65 million series A round. This funding will enable Progentos to advance its MS program through human proof of concept […]

Vertex enters into a definitive agreement to acquire Alpine Immune Sciences

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, yesterday announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and […]

Gilead Sciences announces the acquisition of CymaBay Therapeutics

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced yesterday a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver […]

ViAqua Therapeutics secures USD 8.25Mln investment Led by S2G Ventures

ViAqua Therapeutics Announces $8.25M Investment Led by S2G Ventures to Scale RNA-Based Solutions in Aquaculture

ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a US$8.25M round led by S2G Ventures with participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels and Circle Investments LLC. Aquaculture is essential for improving food security, […]

Heligenics announces precision genetics test for breast cancer therapeutics

The example shows potential treatment options for cancer with Her2 variants.

Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs to treat breast cancer. There are multiple drugs available to treat breast cancer. Most patients become drug resistant, meaning that the cancer cells aren’t responding to the drug that is usually able to kill or weaken them. Although many patients […]

ACROBiosystems Aneuro Partners with Diagnostic Biochips

ACROBiosystems Aneuro Partners with Diagnostic Biochips to Accelerate Neuroscience Drug Discovery

ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization. Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring […]

SeaX Ventures pools $60 Million Fund II for expansion of Global startups in SEA

SeaX Ventures (Southeast Asia Exponential Ventures) announced recently the closure of its second fund to help accelerate the growth of global startups throughout Southeast Asia. According to the firm’s sources, this fund is dedicated to investing in firms operating on truly transformational prospects in sectors comprising blockchain & web3, foodtech, biotech & life science, artificial […]